← Back

Wire · opportunities

Could Electricity Zap Away Chronic Disease?

Published

17 August 2026

Topic

opportunities

Sectors

Medtech

Geography

United States

Source

Read at nationalgeographic.com

Verified

Fusion42 · 17 August 2026 · Fusion42 review

FDA approval of a novel bioelectronic nerve stimulator for rheumatoid arthritis demonstrates a new treatment modality that reduces inflammation via vagus nerve stimulation, with ongoing trials targeting other autoimmune diseases.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ The Wire takeaway

Medtech founders developing chronic disease treatments face a sudden shift from drugs to targeted nerve stimulation devices. You can now explore new development paths that sidestep traditional drug risks and open faster regulatory routes.

Coverage

1 source · 17 Aug 2026

Related on Wire

Topics

Medtechbioelectronic-medicinevagus-nerve-stimulationautoimmune-diseaseFDA-approvalmedical-device